Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Evaluation of Different Concentrations of Imatinib on the Viability of Leishmania Major: An in Vitro Study Publisher



Moslehi M1 ; Namdar F2 ; Esmaeilifallah M2 ; Hejazi SH1, 2 ; Sokhanvari F1 ; Siadat AH3 ; Hosseini SM4 ; Iraji F3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Biostatistics and Epidemiology, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Advanced Biomedical Research Published:2019


Abstract

Background: Leishmaniasis is an infectious disease caused by an intracellular parasite of Leishmania and is transmitted through the female sandflies bite and may lead to severe skin lesions. Although drugs such as antimony compounds are available, their side effects such as toxicity, low efficacy, and emergence of resistance have raised the importance of effective replacement. Imatinib, as an inhibitor of tyrosine kinase (TK) of Leishmania, stops abnormal function of TK such as Bcr-Abl through assembling into transmembrane pores in a sterol-dependent manner. Hence, the evaluation of killing effects of different concentrations of imatinib against Leishmania major amastigotes and promastigotes in vitro were the objectives of the present study. Materials and Methods: The killing effects of different concentrations of imatinib (25, 50, and 100 µg) and 25 µg amphotericin B (as positive control) were evaluated against RPMI 1640-cultured promastigotes and the amastigote/macrophage model by MTS cell proliferation assay kit (ab197010) and Giemsa staining method during 24, 48, and 72 h. Results: The results showed anti-Leishmania effect of imatinib in concentration and time-dependent manner. The lowest number of live promastigotes and amastigotes were obtained due to treat with 100 µg/ml imatinib at 72 h. Furthermore, 100 µg concentration of imatinib had the same effect as 25 µg amphotericin B on both L. major promastigotes and amastigotes (P < 0.001). Conclusion: The anti-Leishmania effect of imatinib was confirmed by MTS and direct microscopy. Further study is recommended for evaluating possible therapeutic effects of imatinib on leishmaniasis in vivo. © 2019 Advanced Biomedical Research | Published by Wolters Kluwer - Medknow.
Related Docs
View other Related Docs
1. Study of Therapeutic Effect of Different Concentrations of Imatinib on Balb/C Model of Cutaneous Leishmaniasis, AIMS Microbiology (2020)
2. Butanol Fraction of Kelussia Odoratissima Mozaff Inhibits the Growth of Leishmania Major Promastigote and Amastigote, World's Veterinary Journal (2020)
3. A Survey on Inhibitory Effect of Whole-Body Extraction and Secretions of Lucilia Sericata’S Larvae on Leishmania Major in Vitro, Advanced Biomedical Research (2020)
4. Investigating in Vitro Anti-Leishmanial Effects of Silibinin and Silymarin on Leishmania Major, Annals of parasitology (2018)
5. Development of Liposomes Loaded With Anti-Leishmanial Drugs for the Treatment of Cutaneous Leishmaniasis, Journal of Liposome Research (2013)
6. Antimonial Treatment Failure Rate in Patients With Cutaneous Leishmaniasis, Tehran University Medical Journal (2018)
7. A Lentiviral Vaccine Expressing Kmp11-Haspb Fusion Protein Increases Immune Response to Leishmania Major in Balb/C, Parasitology Research (2018)
8. The Role of Metacaspases and Other Proteins Involved in the Apoptosis of Leishmania: Review Article, Iranian Journal of Parasitology (2025)
Experts (# of related papers)
View all Related Experts
Seyed Hossein Hejazi (63)
Sedighe Saberi (16)
Other Related Docs
9. Review of the Prevalence and Causes of Antimony Compounds Resistance in Different Societies: Review Article, Tehran University Medical Journal (2017)
10. The Role of Liposomal Cpg Odn on the Course of L. Major Infection in Balb/C Mice, Iranian Journal of Parasitology (2010)
11. In Vitro Assessment of Dracocephalum Lindbergii for Growth Inhibition, Apoptosis Induction, and Cytokine Modulation Against Leishmania Major, Heliyon (2024)
12. Preparation and Characterization of Itraconazole Loaded Nanomicelles Based on Dextran–Behenic Acid for Cutaneous Leishmaniasis Treatment, Drug Development and Industrial Pharmacy (2021)
13. Treatment Role of Terpenoid Fraction of Perovskia Abrotanoides Kar. on Zoonotic Cutaneous Leishmaniasis in Animal Model, Traditional and Integrative Medicine (2022)
14. The Effects of Prednisolone and Mometasone on Wound Healing Caused by Leishmania Major in Balb/C Mice, Journal of Isfahan Medical School (2020)
15. Evaluation of the Antileishmanial Effect of Polyclonal Antibodies and Cationic Antimicrobial Peptides, Pathogens and Global Health (2023)
16. Efficacy of Paromomycin Ointment in the Treatment of Cutaneous Leishmaniasis: Results of a Double-Blind, Randomized Trial in Isfahan, Iran, Annals of Tropical Medicine and Parasitology (2005)
17. Effect of Combination Therapy With Systemic Glucantime and Pentoxifylline in the Treatment of Cutaneous Leishmaniasis, International Journal of Dermatology (2006)
18. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Itraconazole in the Treatment of Cutaneous Leishmaniasis, Journal of the European Academy of Dermatology and Venereology (2005)
19. The Effect of Medium in Properties and Activity of Acid Phosphatase (Acp) in the Infective Form of Leishmania Major Promastigotes, Journal of Isfahan Medical School (2014)
20. Anti-Leishmaniasis Effect of Staphylococcus Aureus Protein a on the Size of the Lesion and Parasitic Load, Advanced Biomedical Research (2023)
21. In Vitro Study of the Leishmanicidal Activity of Perovskia Abrotanoides Terpenoid-Rich Fractions Against Leishmania Major (Mrho/Ir/75/Er), Advanced Biomedical Research (2023)
22. The Study of the Inhibitory Effects of Aqueous and Ethanolic Extracts of Ziziphora Tenuior L. on the Proliferation of Leishmania Major Amastigotes, Iranian Journal of Dermatology (2018)
23. The Characterization and Antileishmanial Evaluation on Leishmania Major With Chitosan/Zno Bio-Nanocomposite As Drug Delivery Systems, Nanomedicine Research Journal (2022)
24. Combinatorial Delivery of Antigen and Tlr Agonists Via Plga Nanoparticles Modulates Leishmania Major-Infected-Macrophages Activation, Biomedicine and Pharmacotherapy (2021)
25. Therapeutic Effect of Topical Tamoxifen in Murine Cutaneous Leishmaniasis Caused by Leishmania Major, Antimicrobial Agents and Chemotherapy (2024)
26. Topical Effectiveness of Different Concentrations of Nanosilver Solution on Leishmania Major Lesions in Balb/C Mice, Journal of Vector Borne Diseases (2012)
27. Anti-Leishmania Activity of Osthole, Pharmacognosy Research (2016)
28. Characterization of Acid Phosphatase in the Promastigotes of Three Isolates of Leishmania Major, Iranian Journal of Medical Sciences (2003)
29. Synthesis and Comparison of Anti-Leishmania Major Activity of Antimony and Iron Complexes of 3-Hydroxypyran-4-One and 3-Hydroxypyridine-4-One As Bi-Dentate Ligands, Journal of Reports in Pharmaceutical Sciences (2020)
30. Synthesis and Antileishmanial Activity of Antimony (V) Complexes of Hydroxypyranone and Hydroxypyridinone Ligands, Research in Pharmaceutical Sciences (2018)
31. The Role of Bax in the Apoptosis of Leishmania-Infected Macrophages, Microbial Pathogenesis (2020)
32. Detection of Leishmania Parasites From Cutaneous Leishmaniasis Patients With Negative Direct Microscopy Using Nnn and Pcr-Rflp, Journal of Isfahan Medical School (2012)
33. Recombinant C-Reactive Protein: A Potential Candidate for the Treatment of Cutaneous Leishmaniasis of Balb/C Mice Caused by Leishmania Major, Acta Parasitologica (2021)
34. Effects of S-Allyl-Cysteine on Survival, Apoptosis, and Proliferation of Leishmania Major in Vitro, Journal of Isfahan Medical School (2013)
35. In Vitro Anti-Leishmanial Activity of Satureja Hortensis and Artemisia Dracunculus Extracts on Leishmania Major Promastigotes, Journal of Parasitic Diseases (2016)
36. Cutaneous Necrosis After the Injection of Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis: A Rare Case Report, Journal of Isfahan Medical School (2019)
37. Treatment of Cutaneous Leishmaniasis: Cassia Fistula Fruit Gel-Intralesional Glucantime Vs. Placebo Gel- Intralesional Glucantime Combination, Tehran University Medical Journal (2010)
38. Serum Monocyte Chemotactic Protein-1 and Nitric Oxide in Cutaneous Leishmaniasis Patients Before and After Treatment With Glucantime, Journal of Isfahan Medical School (2012)
39. Comparison of Intralesionally Injected Zinc Sulfate With Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis, Dermatology (2004)
40. A Randomised, Double-Blind, Controlled Trial of a Killed L. Major Vaccine Plus Bcg Against Zoonotic Cutaneous Leishmaniasis in Iran, Vaccine (1999)
41. Anti-Leishmanial Effects of Resveratrol and Resveratrol Nanoemulsion on Leishmania Major, BMC Microbiology (2022)
42. Comparative Molecular Epidemiology of Leishmania Major and Leishmania Tropica by Pcr-Rflp Technique in Hyper Endemic Cities of Isfahan and Bam, Iran, Case Reports and Clinical Practice Review (2010)
43. Bacterial Superinfection in Zoonotic Cutaneous Leishmaniasis, Medical Science Monitor (2012)
44. Electrocardiographic Changes in Patients With Cutaneous Leishmaniasis Treated With Systemic Glucantime, Annals of the Academy of Medicine Singapore (2008)
45. The Efficacy of 5% Trichloroacetic Acid Cream in the Treatment of Cutaneous Leishmaniasis Lesions, Journal of Dermatological Treatment (2012)
46. Molecular Identification and Phylogenetic Classification of Leishmania Spp. Isolated From Human Cutaneous Leishmaniasis in Iran: A Cross-Sectional Study, Iranian Journal of Parasitology (2018)
47. A Comparison Between the Effects of Glucantime, Topical Trichloroacetic Acid 50% Plus Glucantime, and Fractional Laser Plus Glucantime on Cutaneous Leishmaniasis Lesions, Journal of Isfahan Medical School (2013)
48. Heat Therapy for Cutaneous Leishmaniasis: A Literature Review, Journal of Research in Medical Sciences (2021)
49. The Skin Side Effects of Topical Glucantime in Patients With Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2015)
50. Effect of Adjunctive Topical Liposomal Azithromycin on Systemic Azithromycin on Old World Cutaneous Leishmaniasis: A Pilot Clinical Study, Iranian Journal of Pharmaceutical Research (2021)